Bristol-myers Squibb Compnay

Bristol Meyers Squibb Company

Junying Fan

Zhen-Wei Cai

Stephanie Barbosa

Luca Parlanti

Ashvinikumar V Gavai

Rajeev S Bhide

Derek J Norris

Bin Zheng

Ligang Qian

Edward J Delaney

Shankar Swaminathan

Francis S Gibson

Gerard Crispino

Peng Geng

Neil A Strotman

Alina Borovika

Reginald O Cann

Dimitri Skliar

Bharat P Patel

Richard Michael Corbett

Jason Michael Stevens

Disclosed is a process for preparing (S)-4-(3-(but-2-ynamido)piperidin fluoro-2,3-dimethyl-1H-indole-7-carboxamide, comprising the steps of: preparing a compound of Formula (III); converting the compound of Formula (III) to a compound of Formula (V); and reacting the compound of Formula (V) with a compound of Formula (VI) to provide (S)-4-(3-(but-2-ynamido)piperidin-1-yl)-5-fluoro-2,3-dimethyl-1H-indole-7-carboxamide. 

Process for preparing indole carboxamide compounds

The present invention is directed to intermediates that are useful for preparing pyrrolotriazines, and processes for preparing such intermediates.

Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors

A process is provided for the process for preparing a pyrrolotriazine aniline p38 kinase inhibitor such as amide II by the direct aminolysis of the ester I wherein ester I is reacted with a strong organometallic base, such as hexyllithium or n-butyllithium and the desired amine such as n-propylamine to form the amide II.

Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors

The present invention provides a process for preparing compounds of formula (I) or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

Process for preparing pyrrolotriazine

The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formulaand pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

Process for preparing certain pyrrolotriazine compounds

Growing community of inventors

Monmouth Junction, NJ, United States of America

Junying Fan